Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078874 | 0.89 | METAP2 (0.32) | RAB9ANPC1SMN1; SMN2ATM | |
| SCHEMBL3508077 | 0.80 | METAP2 (0.45) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL23416081 | 0.79 | MAPK14 (0.47) | MAPT | |
| SCHEMBL20848 | 0.78 | KMT2A (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL3283468 | 0.78 | — | — | |
| SCHEMBL1823584 | 0.78 | METAP2 (0.44) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL6166437 | 0.78 | METAP2 (0.44) | — | |
| SCHEMBL5612785 | 0.78 | RPA1 (0.44) | RAB9ANPC1ALOX5CA12ALPL | |
| SCHEMBL12989702 | 0.78 | AKT1 (0.48) | RAB9ANPC1MEN1KMT2AALDH1A1 | |
| SCHEMBL718333 | 0.78 | MAPT (0.45) | RAB9ANPC1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | claimed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | claimed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | claimed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | claimed |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4496837-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-119213061-A | Cross-linked protein, method for producing the same and use thereof | 纽约州立大学研究基金会 | 2024-12-27 | — | — | CN | disclosed |
| CN-117903071-A | Synthesis method of alpha-aminoketone derivative | 湖州师范学院 | 2024-04-19 | — | — | CN | disclosed |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20030220371-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2003-11-27 | — | — | US | disclosed |
| EP-1274424-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1274424-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001078723-A1 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192914-A1 | Compounds and methods | METAP2, METAP1, DNPEP | RAB9A 906/4885NPC1 3027/4885MEN1 2227/4885 |
| US-20030220371-A1 | Compounds and methods | METAP2, METAP1, DNPEP | RAB9A 1701/4885NPC1 2301/4885MEN1 2323/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | RAB9A 2943/4885NPC1 352/4885MEN1 1088/4885 |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | RAB9A 2956/4885NPC1 4790/4885MEN1 2811/4885 |
| US-20050143578-A1 | Compounds and methods | METAP2, METAP1, DNPEP | RAB9A 939/4885NPC1 3179/4885MEN1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.